T. Rowe Price Associates
DSGN icon

T. Rowe Price Associates’s Design Therapeutics DSGN Stock Holding History

T. Rowe Price Associates’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$175K Buy
16,370
+659
+4% +$6.67K ﹤0.01% 2879
2025
Q4 		$148K Sell
15,711
-603
-4% -$4.72K ﹤0.01% 2880
2025
Q3 		$123K Hold
16,314
– – ﹤0.01% 2891
2025
Q2 		$55K Buy
16,314
+3,245
+25% +$12.1K ﹤0.01% 2994
2025
Q1 		$51K Buy
13,069
+618
+5% +$2.95K ﹤0.01% 2927
2024
Q4 		$77K Buy
12,451
+2,167
+21% +$12.5K ﹤0.01% 2881
2024
Q3 		$56K Hold
10,284
– – ﹤0.01% 2914
2024
Q2 		$35K Sell
10,284
-863
-8% -$3.36K ﹤0.01% 2886
2024
Q1 		$45K Buy
+11,147
New +$29.8K ﹤0.01% 2884
2022
Q4 		– Sell
-280,120
Closed -$4.68M – 2945
2022
Q3 		$4.68M Sell
280,120
-72,989
-21% -$1.45M ﹤0.01% 1222
2022
Q2 		$4.94M Sell
353,109
-220,903
-38% -$2.98M ﹤0.01% 1424
2022
Q1 		$9.27M Sell
574,012
-213,653
-27% -$3.27M ﹤0.01% 1377
2021
Q4 		$16.9M Sell
787,665
-661,303
-46% -$11.4M ﹤0.01% 1324
2021
Q3 		$21.3M Hold
1,448,968
– – ﹤0.01% 1278
2021
Q2 		$28.2M Buy
1,448,968
+13,714
+1% +$346K ﹤0.01% 1216
2021
Q1 		$41.9M Buy
+1,435,254
New +$48.4M ﹤0.01% 1064

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's DSGN Position: Q1 2026 in Review

T. Rowe Price Associates increased its Design Therapeutics (DSGN) stake by 4.2% in Q1 2026, buying an estimated $6.67K and bringing the position to 16,370 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #2879.

T. Rowe Price Associates first reported a position in DSGN in Q1 2021 and has held it in 16 quarters since. The position peaked at $41.9M in Q1 2021. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • T. Rowe Price Associates held 16,370 shares of Design Therapeutics worth $175K as of Q1 2026.
  • T. Rowe Price Associates bought 659 Design Therapeutics shares in Q1 2026, an estimated $6.67K.
  • Design Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2879 holding.
  • T. Rowe Price Associates first reported a position in Design Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • T. Rowe Price Associates's Design Therapeutics position peaked at $41.9M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.